Background: Current strategies for the prevention, diagnosis and treatment of pleural TB have been inadequate, several challenges and issues related with pleural TB have been reported. Aim: To summarize the main features of pleural tuberculosis (TB) and determine the risk factors in treatment delay. Design: Retrospective analysis of hospital records. Methods: Consecutive confirmed TB patients with pleural effusion were enrolled in the study. Demographic and epidemiological data were collected from electronic medical records. Treatment delay duration was stratified into two categories: <30 days and 30 days. Multivariate logistic regression analysis was used to evaluate risk factors for the delay. Results: From July 2011 to September 2015, a total of 723 patients were enrolled, 72.1% of patients had pulmonary TB, 8.9% had empyema, 8.9% were multidrug-resistant TB (MDR-TB). Multivariate analysis revealed that MDR-TB (odds ratios (OR) ¼ 2.485, 95% confidence interval (CI) 1.347, 4.587), pulmonary TB (OR ¼ 1.452, 95% CI 1.010, 2.087) and empyema (OR ¼ 4.355, 95% CI 2.185, 8.680) were significant risk factors for treatment delay, while fever (OR¼ 0.519, 95% CI 0.362, 0.744) as well as pleural protein (45 g/l) (OR¼0.470, 95% CI 0.332, 0.667) were the protective factors. Conclusion: MDR-TB, pulmonary TB and empyema were significant risk factors for treatment delay, while fever and high pleural protein were protective factors. Tuberculous empyema remains a major problem in China, adequate awareness should be created for the management.
Introduction
Tuberculosis (TB) remains a major global health problem. According to WHO, in 2015, there was an estimated 10.4 million new TB cases, 15% were extrapulmonary TB (EPTB), and 480 000 cases presented as multidrug-resistant TB (MDR-TB) worldwide.
1 A study conducted in Tianjin showed, about onetenth of TB patients had EPTB, and two-thirds were pleural TB. 2 Pleural TB therefore, seems to be frequent in the high TB burden country. Current strategies for the prevention, diagnosis and treatment of pleural TB have been inadequate. Recently, many studies have highlighted several challenges and issues related with pleural TB. First, because of the rapid change in lifestyle in China, the prevalence of total diabetes have been reported to be as high as 9.7% (total diabetes) and 15.5% (pre-diabetes), respectively, diabetes has become a major public health problem in China. 3 Diabetes could increase the risk of failure and death combined, death and relapse among patients with TB, so strategies aimed at the prevention and treatment of TB in diabetes are needed. 4 Second, now, human immunodeficiency virus (HIV) epidemic contribute to the significant part of TB. 5, 6 Moreover, low cure rate of TB among patients with HIV was also reported. 7 Thus, program to address the dual infections of HIV/ TB is needed. Third, the current serious global MDR-TB prevalence make the treatment of TB increasingly difficult. 1 More efforts are necessary to develop better strategies in management of TB. Fourth, the diagnosis of pleural TB remains relying on routine assays, such as smear, culture and histological examinations. 8 Significant patient delay and total delay was also reported, as such in pulmonary TB. 9 In a word, it was necessary to conduct an investigation into the characteristics of pleural TB to establish effective treatment strategies and to improve the diagnosis and prognosis. This study aimed to (i) summarize the main features of pleural TB in China, including underlying diabetes, HIV infection, empyema, drug resistance, initial or retreatment therapy; and (ii) identify the risk factors in treatment delay of pleural TB.
Materials and methods
This study was approved by the Human Research Ethics Committees of Shandong Provincial Chest Hospital (Ethics approval number: SPCHEC 2015-06-03), no informed consent was required because of the retrospective study design, data were analyzed anonymously. This retrospective study was carried out in Jinan city, China during the period from July 2011 to September 2015. The raw data are available from the corresponding author upon request.
Consecutive patients who admitted to our hospital presenting with pleural effusion (PE), and subsequent culture confirmed a diagnosis of pleural TB were enrolled in our study. Demographic and epidemiological data were collected using a questionnaire from electronic medical records to include age, sex, symptoms, HIV status, time before admission to the hospital, smoking habit and underlying diseases.
PE samples obtained by thoracocentesis underwent biochemical and microbiological analysis. An automated chemistry analyzer was used to examine biochemical parameters, such as total protein, lactate dehydrogenase (LDH) and adenosine deaminase (ADA). Mycobacterium tuberculosis isolated from PE samples were subjected to drug susceptibility testing by using the absolute concentration method (isoniazid: 1 lg/ml, rifampicin: 50 lg/ml) on Lowenstein-Jensen medium. 10 Several TB diagnostic methods were performed routinely, including acid-fast bacilli (AFB, auramine O stain), TB real time-polymerase chain reaction (RT-PCR) and surgical methods (pathological examination, such as thoracoscopy, percutaneous needle biopsy and endobronchial biopsy).
We also conducted a cohort study to determine the risk factors associated with treatment delay for pleural TB. Treatment delay duration was defined as the time interval from onset of symptoms (by patient recall) to initiation of treatment and was stratified into two categories: <30 days and 30 days (median delay day is 30 days).
Patient characteristics were summarized using means and standard deviations for continuous variables and counts/percentages for categorical variables. Univariate analysis was carried out using the v 2 test or Fisher's exact test for categorical data and the Mann-Whitney U test for continuous variables. Beyond descriptive statistics, associations between the dependent variables (treatment delay) and the independent variables were analyzed by calculating the odds ratios (OR) and 95% confidence interval (CI). Multivariate logistic regression analysis was used to evaluate risk factors for the delay, using selection of factors associated with delay in univariate analysis (P < 0.1) or those known to have clinical significance. The HosmerLemeshow goodness-of-fit test was performed to assess the overall fit of the model. A two-sided P values <0.05 was considered significant for all analyses. Data analysis was carried out using SPSS 18.0 (IBM Corp., Armonk, USA).
Results
Characteristics of patients Fever (71.6%) was the most frequently reported symptom followed by cough (69.2%), dyspnea (50.1%) and chest pain (38.3%). Chest X-ray showed that 54.5% of effusions were on the right, 35.8% on the left, 9.7% on the both. Fourteen (1.9%) TPEs were misclassified as transudates using Light's criteria. Biochemical results of PE were also summarized in Table 1 .
One hundred forty-four of 711 patients (20.3%) who underwent AFB for TB bacilli had a positive finding, 299 of 613 patients (48.8%) who underwent TB RT-PCR had a positive finding, and 225 of 295 patients (76.3%) who underwent pathological examination had a positive finding (60/62 (96.8%) for surgical tissues, 9/27 (33.3%) for percutaneous needle biopsy (6/22, 27.3%) and endobronchial biopsy (3/5, 60.0%), and 156/206 (75.7%) for thoracoscopy).
Treatment delay
The median treatment delay for all patients included in the study was 30 days (interquartile range 15-60 days). For 428 (59.2%) patients, the treatment delay was 30 days. Table 1 shows the univariate analysis on risk factors, comparing patients with total delay of 30 days with patients with total delay of <30 days. The delay was associated with age, smoking habit, MDR-TB, empyema, symptoms (fever, cough and chest pain), pleural biochemical tests (protein, LDH and ADA) (all P < 0.05) ( 
Discussion
TPE is one of the most common forms of EPTB in China and is one of the most frequent causes of PE. Although various PE biomarkers have been evaluated for the diagnosis of pleural TB, there remain some limitations in making a definitive diagnosis, so treatment delay usually occurs in hospital. 11 Aiming to assess characteristics and factors associated with treatment delay in pleural TB, this study was conducted to review demographic characteristics, drug susceptibility test results, HIV status and risk factors for treatment delay of pleural TB. In our study, 72.1% of participants had pulmonary TB, 8.6% had EPTB (excluding TPE), 8.9% had empyema, 6.8% had diabetes mellitus, 5.7% had retreatment TB, 8.9% were MDR-TB cases, 0.34% were HIV-positive.
Five features of the prevalence data are noteworthy. First, most of pleural TB usually followed pulmonary TB, so pulmonary TB remains the major target goal for pleural TB control programme. Second, tuberculous empyema which represents a chronic, active infection of the pleural space, is rare and associated with high mortality and morbidity unless surgically treated. 12 In the study, a relatively high proportion of patients were reported having empyema. For management of pleural TB, tuberculous empyema remains a major problem in China. Therefore, adequate awareness should be created for prompt recognition and early institution of appropriate therapy. Third, the rate of recurrent pleural TB is low, and is at similar level with the data reported by WHO, but for pulmonary TB, the rate is 10% at the hospital. 13 Fourth, In China, the prevalence of MDR-TB was found to be 4.8% (4.0%-5.7%). 14 Nevertheless, in the current study, the prevalence of MDR-TB was found to be approximately twice the rate. Fifth, although the prevalence of HIV infection in China has increased significantly for past decade, but it doses contribute a small amount of patients with pleural TB. 15, 16 In the study, the multiple regression analysis revealed that MDR-TB (OR ¼ 2.485), pulmonary TB (OR ¼ 1.452), and empyema (OR ¼ 4.355) were significant risk factors for treatment delay, while fever (OR ¼0.519) as well as pleural protein (45 g/l) (OR ¼0.470) were the protective factors for timely treatment.
MDR-TB patients had longer treatment delay. A possible explanation for this is that before admission to the referral hospital, inappropriate treatment was performed, then leads to a poor treatment outcomes. 17 In a Chinese study, it was reported that 38.2% of MDR-TB patients were not enrolled in standardized treatment. 18 The rate is much higher than the average global rate of 10%. 19 As you know, early detection and timely and appropriate treatment are vital to the control of MDR-TB. 20 Therefore, comprehensive strategies, especially those improving treatment of MDR-TB, need to be implemented to optimize the treatment of pleural TB. Combined pleural and pulmonary TB patients had a longer delay in treatment than isolated pleural TB patients. It is possibly due to the fact that significant treatment delay was found in pulmonary TB. For example, in Taiwan, 20.3% of pulmonary TB patients experienced a treatment delay. 21 Similar delays were reported in China, Southern Ethiopia and Bangladesh. [22] [23] [24] Empyema was another risk factor for treatment delay of pleural TB. This may contribute to inappropriate treatment of tuberculous empyema. In fact, in the initial stage of the disease, closed chest drainage and antibiotic therapy can comprise effective treatment, it can resolves small uniloculated empyema with an 80% success rate. 25 However, in the later stages, antibiotics are not effective because of pleural peel and fluid loculation. Surgical techniques are necessary to achieve good results. 26 Therefore, when dealing with tuberculous empyema, physicians should be aware of the disease progression. Two factors (fever and pleural protein 45 g/l) have contributed to the relatively shorter treatment delay. A shorter delay in seeking medical help may have reduced the risk of treatment delay in pleural TB. We guessed that patients' perception of fever may be a motivating factor in terms of seeking health care. Pleural protein (45 g/l) was also found to be a protective factor for timely treatment. Classically, pleural protein 30 g/l has indicated an exudate and <30 g/l a transudate. 27, 28 The classification of PEs would narrow down the differential diagnosis and direct further investigations and subsequent management. Hence, when pleural protein was greater than 45 g/l, it would save a lot of time for the diagnosis and early treatment could be initiated.
There are some limitations in our study. First, we were not able to divide treatment delay into patient-related and health system-related delay due to limited information on the first contact to any healthcare provider. Second, recall bias is a potential problem, due to the retrospective method of data collection with resulting uncertainty of the actual onset of symptoms. However, data were collected in a similar way, and the bias, if it exists, is non-differential and conservative. Third, the results of our study need to be carefully interpreted because these data were based on a single hospital experience, which was not enough to represent the characteristics of pleural TB in the entire Chinese population. In addition, although several risk factors were discovered, additional studies are required to validate our findings.
Conclusions
Delay of pleural TB treatment in China is significantly associated with disease severity. MDR-TB, pulmonary TB and empyema were significant risk factors for treatment delay, while fever and high pleural protein were protective factors. Despite the availability of potent anti-tubercular drugs and improved surgical techniques, tuberculous empyema remains a major problem in China. Therefore, adequate awareness should be created for prompt recognition and early institution of appropriate therapy.
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